W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Miasta: Gdańsk, Gliwice, Kraków, Poznań i 2 inne miastaWiek: od 0 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza I
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Miasta: Gdańsk, Katowice, Kraków, SkórzewoWiek: od 65 latSponsor: Janssen Cilag International
RekrutujeFaza III
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small…
Miasta: Gdańsk, Gliwice, Katowice, Kraków i 4 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
Global Trial in APG2575 for Patients With CLL/SLL
Miasta: Bydgoszcz, Kraków, Skórzewo, ŁódźWiek: od 18 latSponsor: Ascentage Pharma Group Inc.
RekrutujeFaza II
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Miasta: Biała Podlaska, Brzozów, Gdynia, Kielce i 3 inne miastaWiek: od 18 latSponsor: Janssen - Cilag International
RekrutujeFaza III
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Miasta: Biała Podlaska, Bydgoszcz, Gdańsk, Katowice i 4 inne miastaWiek: od 18 latSponsor: Loxo Oncology Inc.
W Polsce: ZakończoneNa świecie: RekrutujeFaza I/II
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Miasta: Biała Podlaska, OlsztynWiek: od 18 latSponsor: Ascentage Pharma Group Inc.
RekrutujeFaza I/II
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Miasta: Gdańsk, Kraków, WarszawaWiek: od 18 latSponsor: Curis Inc.